Clinical trials
Muscular Dystrophy clinical trials
Below are recruiting muscular dystrophy clinical trials, each written for real people, not researchers. We’re tracking 133 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04369209Recruiting
Study of people with FSHD1 gene changes
This is a study that follows people who have a confirmed FSHD1 genetic change (and some healthy people for comparison). It may help researchers better understand the condition and how it affects people over time.
Fuzhou, FujianAges Any age - NCT05066633RecruitingPhase 3
Metoprolol added to standard care to prevent heart muscle damage
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
Gdansk, Pomeranian VoivodeshipAges 8–17 - NCT05102916Recruiting
Registry for neuromuscular disorder patients in Switzerland
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
Aarau, Canton of AargauAges birth+ - NCT05102799Recruiting
MRI study for people with anoctamin-5 muscle gene changes
This trial uses MRI scans of your lower back and leg muscles to better understand how anoctamin-5 gene changes affect muscle structure. It may help researchers learn patterns that could improve future care, and you would be expected to have specific genetic results and a scan.
CopenhagenAges Any age - NCT05237973Recruiting
Neuromuscular ultrasound study for healthy people and patients
This study uses an ultrasound scan to look at muscles and nerves (including the breathing muscle). It may help researchers better understand neuromuscular problems and how well ultrasound can detect them.
Bethesda, MarylandAges 18–110 - NCT05412394RecruitingPhase 4
Once-weekly steroid for very young children with DMD
This trial tests whether a steroid taken once each week is safe and useful for children with Duchenne muscular dystrophy (DMD). It aims to help slow disease effects in very young children whose diagnosis and lab tests confirm DMD.
Chicago, IllinoisAges 1 month–2.5 years - NCT05644522Recruiting
At-home brace study for leg support and walking
This study tests an at-home wearable activity monitor and brace-related walking support for people who already use a knee-ankle-foot brace. It may help researchers understand how brace use and day-to-day movement relate to walking ability.
Chicago, IllinoisAges 18–89 - NCT05724173Recruiting
Test of a brain-to-computer device for ALS hand paralysis
This study checks whether a brain-computer interface (a BrainGate2 system) is safe and workable for people with ALS. If you qualify, you may be asked to try the device and complete study tasks to help researchers learn how well it can support communication or control.
Stanford, CaliforniaAges 18–80 - NCT05726591Recruiting
Robotic exoskeleton study to improve walking in children
This study looks at how safely using a pediatric robotic exoskeleton over the long term can improve how children walk. It’s for children ages 3–17 who have certain movement or spine-related conditions and who can meet walking and joint-movement requirements.
Bethesda, MarylandAges 3–17 - NCT05989620Recruiting
Long-term study of muscular dystrophy functions
This study tracks changes in muscle strength and breathing over time in people with certain types of muscular dystrophy. It helps researchers develop better tests to measure how the disease progresses.
Richmond, VirginiaAges 6–50 - NCT06079567Recruiting
Study of FSHD2 progression over 18 months
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
LeuvenAges 18–75 - NCT06093100Recruiting
Wearable device study for Duchenne muscular dystrophy
This study uses a wearable device to track blood sugar levels and heart rate in people with Duchenne muscular dystrophy. It aims to understand how these factors relate to heart health over time.
Nashville, TennesseeAges 10 years+ - NCT06094205Recruiting
BrainGate2 speech study for people with tetraplegia
This study tests a brain-computer interface to help people with severe paralysis communicate by decoding attempted speech or movements. It may offer a new way to interact with devices using only brain signals.
Sacramento, CaliforniaAges 18–80 - NCT06124196Recruiting
Wearable device study for Duchenne muscular dystrophy
This study uses a wearable device to track your blood sugar levels and heart rate patterns over time. It aims to understand how these are related to Duchenne muscular dystrophy (DMD) and may help improve care.
Nashville, TennesseeAges 10 years+ - NCT06224660RecruitingPhase 1
Gene therapy for heart problems in Duchenne muscular dystrophy
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Kansas City, KansasAges 18 years+ - NCT06227182Recruiting
Comparing MRI and ultrasound for muscle health
This study compares two imaging methods, MRI and ultrasound, to see how well they measure muscle health. It may help find better ways to monitor muscle conditions without invasive tests.
Nijmegen, GelderlandAges 18–70 - NCT06539169Recruiting
Following people with rare diseases over time
This study follows people with rare diseases over time to learn more about how these conditions progress and how they are treated. Joining may help researchers understand your disease better and find better ways to care for others.
Los Altos, CaliforniaAges Any age - NCT06692426RecruitingPhase 1
Cell therapy for Duchenne muscular dystrophy
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
Minneapolis, MinnesotaAges 18 years+ - NCT06721299RecruitingPhase 1
Testing clenbuterol for muscle health in FSHD
This study tests a medication called clenbuterol to see if it can reduce activity of the DUX4 gene, which is believed to cause muscle damage in FSHD. If you have FSHD type 1 or 2, you may be able to join and help researchers understand if this drug can improve muscle health.
Kansas City, KansasAges 18–75 - NCT06769633RecruitingPhase 2
Study of givinostat in young boys with Duchenne muscular dystrophy
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
BrusselsAges 2–6 - NCT06847282Recruiting
Motor skills study for children with FSHD
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
Palo Alto, CaliforniaAges 5–17 - NCT06911190Recruiting
10-year follow-up study for FSHD patients
This study follows FSHD patients for 10 years to see how the disease progresses. It includes people who were in earlier FSHD studies and some new patients with genetic confirmation of FSHD.
NijmegenAges 6 years+ - NCT06925269Recruiting
DMD Voice: Interviews with patients and caregivers
This study invites people with Duchenne muscular dystrophy (DMD) and their caregivers to share their experiences through interviews. It focuses on those who have been taking the medication Givinostat for at least two years, or caregivers of patients with limited arm movement.
Yardley, PennsylvaniaAges 10 years+ - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9
Hear when a new Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscular dystrophy?
- Yes. Clin2 currently lists 133 recruiting muscular dystrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscular dystrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscular dystrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.